Mendel Money Management Decreases Position in Eli Lilly and Company $LLY

Mendel Money Management trimmed its position in shares of Eli Lilly and Company (NYSE:LLY) by 5.5% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 1,751 shares of the company’s stock after selling 102 shares during the quarter. Mendel Money Management’s holdings in Eli Lilly and Company were worth $1,365,000 at the end of the most recent reporting period.

A number of other institutional investors also recently bought and sold shares of LLY. Brighton Jones LLC boosted its position in Eli Lilly and Company by 22.0% during the fourth quarter. Brighton Jones LLC now owns 9,597 shares of the company’s stock worth $7,409,000 after purchasing an additional 1,730 shares in the last quarter. Revolve Wealth Partners LLC lifted its position in shares of Eli Lilly and Company by 2.8% in the fourth quarter. Revolve Wealth Partners LLC now owns 1,471 shares of the company’s stock valued at $1,136,000 after acquiring an additional 40 shares in the last quarter. Covestor Ltd lifted its position in shares of Eli Lilly and Company by 24.9% in the first quarter. Covestor Ltd now owns 426 shares of the company’s stock valued at $352,000 after acquiring an additional 85 shares in the last quarter. Kaufman Rossin Wealth LLC purchased a new stake in shares of Eli Lilly and Company in the first quarter valued at $242,000. Finally, Golden State Wealth Management LLC lifted its position in shares of Eli Lilly and Company by 9.1% in the first quarter. Golden State Wealth Management LLC now owns 1,019 shares of the company’s stock valued at $842,000 after acquiring an additional 85 shares in the last quarter. 82.53% of the stock is currently owned by hedge funds and other institutional investors.

Eli Lilly and Company Trading Down 0.6%

Shares of LLY opened at $821.60 on Wednesday. The company has a market capitalization of $777.61 billion, a P/E ratio of 53.70, a P/E/G ratio of 1.23 and a beta of 0.47. Eli Lilly and Company has a one year low of $623.78 and a one year high of $935.63. The company has a debt-to-equity ratio of 1.86, a quick ratio of 1.00 and a current ratio of 1.28. The stock has a 50-day moving average price of $772.90 and a 200 day moving average price of $769.79.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings results on Thursday, August 7th. The company reported $6.31 EPS for the quarter, beating analysts’ consensus estimates of $5.59 by $0.72. The firm had revenue of $15.56 billion during the quarter, compared to the consensus estimate of $14.40 billion. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.Eli Lilly and Company’s revenue for the quarter was up 37.6% on a year-over-year basis. During the same quarter in the prior year, the business posted $3.92 earnings per share. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. Sell-side analysts forecast that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, December 10th. Shareholders of record on Friday, November 14th will be issued a dividend of $1.50 per share. This represents a $6.00 dividend on an annualized basis and a yield of 0.7%. The ex-dividend date of this dividend is Friday, November 14th. Eli Lilly and Company’s dividend payout ratio (DPR) is currently 39.22%.

Insider Activity at Eli Lilly and Company

In other news, Director J Erik Fyrwald bought 1,565 shares of Eli Lilly and Company stock in a transaction on Tuesday, August 12th. The shares were bought at an average price of $642.33 per share, with a total value of $1,005,246.45. Following the acquisition, the director directly owned 74,578 shares in the company, valued at approximately $47,903,686.74. This represents a 2.14% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Daniel Skovronsky bought 1,000 shares of Eli Lilly and Company stock in a transaction on Tuesday, August 12th. The shares were purchased at an average cost of $634.40 per share, for a total transaction of $634,400.00. Following the acquisition, the executive vice president owned 137,660 shares in the company, valued at $87,331,504. The trade was a 0.73% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have purchased a total of 4,514 shares of company stock worth $2,894,841 over the last quarter. 0.14% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

LLY has been the topic of several recent analyst reports. The Goldman Sachs Group increased their target price on Eli Lilly and Company from $876.00 to $879.00 and gave the stock a “buy” rating in a research report on Friday, October 10th. UBS Group dropped their price target on Eli Lilly and Company from $1,050.00 to $895.00 and set a “buy” rating for the company in a research note on Friday, August 8th. Hsbc Global Res upgraded Eli Lilly and Company from a “moderate sell” rating to a “hold” rating in a research note on Wednesday, August 27th. Leerink Partnrs lowered Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a research note on Thursday, August 7th. Finally, Weiss Ratings restated a “hold (c+)” rating on shares of Eli Lilly and Company in a research note on Wednesday, October 8th. One research analyst has rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and nine have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $938.61.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.